Gyre Therapeutics, Inc. (NASDAQ:GYRE) Receives $17.00 Consensus PT from Brokerages

Shares of Gyre Therapeutics, Inc. (NASDAQ:GYRE) have been assigned an average recommendation of “Hold” from the five analysts that are presently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating on the company. The average 1-year price objective among brokers that have updated their coverage on the stock in the last year is $17.00.

Several research firms recently weighed in on GYRE. Wall Street Zen upgraded shares of Gyre Therapeutics from a “hold” rating to a “buy” rating in a research report on Saturday, November 15th. Weiss Ratings reissued a “sell (d)” rating on shares of Gyre Therapeutics in a report on Thursday, January 22nd. Finally, Zacks Research upgraded Gyre Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Friday, November 14th.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in GYRE. Geode Capital Management LLC grew its holdings in shares of Gyre Therapeutics by 13.0% during the fourth quarter. Geode Capital Management LLC now owns 423,222 shares of the company’s stock worth $2,989,000 after buying an additional 48,602 shares in the last quarter. SBI Securities Co. Ltd. lifted its stake in shares of Gyre Therapeutics by 87.9% in the second quarter. SBI Securities Co. Ltd. now owns 232,299 shares of the company’s stock worth $1,707,000 after buying an additional 108,670 shares in the last quarter. State Street Corp lifted its stake in shares of Gyre Therapeutics by 10.7% in the fourth quarter. State Street Corp now owns 202,225 shares of the company’s stock worth $1,428,000 after buying an additional 19,472 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its position in Gyre Therapeutics by 37.1% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 169,158 shares of the company’s stock worth $1,194,000 after acquiring an additional 45,772 shares during the last quarter. Finally, Millennium Management LLC purchased a new stake in Gyre Therapeutics during the 3rd quarter valued at about $267,000. Hedge funds and other institutional investors own 23.99% of the company’s stock.

Gyre Therapeutics Stock Performance

NASDAQ:GYRE opened at $8.65 on Monday. The stock has a market capitalization of $833.25 million, a PE ratio of 288.43 and a beta of 1.97. Gyre Therapeutics has a fifty-two week low of $6.11 and a fifty-two week high of $13.75. The company has a fifty day moving average of $7.73 and a two-hundred day moving average of $7.76.

About Gyre Therapeutics

Gyre Therapeutics, Inc is a clinical-stage biotechnology company focused on discovering and developing small-molecule therapies that target lipid biology to treat a range of metabolic, inflammatory and neurodegenerative diseases. The company’s proprietary platform combines lipidomic profiling with drug discovery tools to identify compounds that selectively modulate membrane lipid composition and restore normal protein function in disease-relevant cells.

Gyre’s preclinical pipeline includes programs in nonalcoholic steatohepatitis (NASH), Alzheimer’s disease and autoimmune conditions, reflecting its strategy of applying a unified lipid-targeted approach across multiple therapeutic areas.